{"analyses":[{"ciLowerLimit":"0.45","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.68","groupDescription":"Stratified Analysis: The stratification factors were ECOG PS at randomization (0 vs. 1); LDH at randomization (\\<=ULN vs \\>ULN) via local laboratory test; Presence of liver metastases at enrollment (yes vs. no); Prior receipt of PCI (yes vs. no).","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"0.55"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.53","spread":"2.53","upperLimit":"2.83","value":"2.73"},{"groupId":"OG001","lowerLimit":"4.30","spread":"4.30","upperLimit":"6.57","value":"5.36"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"241"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"PFS was defined as the time from randomization to the date of first documented PD as assessed by investigator according to RECIST v1.1 or death, whichever occurs first. PD was defined as appearance of a new lesion(s), unequivocal progression in non-target lesion(s) or at least a 20% increase in the SOD of target lesions, taking as reference the smallest sum on the study including baseline (nadir). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG000","title":"Atezolizumab"},{"description":"Participants received atezolizumab, 1200 mg, Q3W as IV infusion and lurbinectedin, 3.2 mg/m\\^2, Q3W as IV infusion on Day 1 of each 21-day cycle until unacceptable toxicity or PD whichever occurred first.","id":"OG001","title":"Atezolizumab+ Lurbinectedin"}],"paramType":"MEDIAN","populationDescription":"FAS included all participants randomized into the randomized phase, regardless of whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"Up to 26 months","title":"Randomized Phase: Investigator-assessed PFS","type":"SECONDARY","unitOfMeasure":"months"}